- FDA reminds investors about the risks of advisory panelsTwo days, two similar briefing documents and two companies with diving share prices. The FDA this week laid out its concerns with clinical data from both Capricor Therapeutics andEndpoints · 1h ago↗ source
- J&J proposes $5.5B talc settlementAfter more than a decade and three failed bankruptcy attempts, an end to Johnson & Johnson’s talc saga may finally be in sight. The company has proposed a $5.5 billion settlement ...Endpoints · 1h ago↗ source
- FDA offers updated guidance for generics of weight loss blockbustersThe FDA revised its draft guidance for generic companies looking to develop copycats of some of the world's best-selling weight loss drugs, including Eli Lilly's Zepbound and Novo Nordisk's Ozempic…Endpoints · 1h ago